Abstract: Provided is a method capable of separating and purifying astatine-211 in a high yield and dissolving same in a solution. A method for producing astatine-211, including a step of irradiating ? ray to bismuth to produce astatine-211 in the bismuth, and a step of distilling the bismuth that received ? ray irradiation with a carrier gas containing an inert gas, O2 and H2O to separate and purify astatine-211, and dissolving the astatine-211 in a solution.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
October 24, 2023
Assignee:
OSAKA UNIVERSITY
Inventors:
Atsushi Shinohara, Atsushi Toyoshima, Takashi Yoshimura, Akimitsu Kanda
Abstract: Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
September 19, 2023
Assignee:
Korea Hydro & Nuclear Power Co., Ltd.
Inventors:
Yonghee Kim, Jiyoung Lee, Seongdong Jang, Ur Rehman Haseeb, Eun Ki Lee, Young Ae Kim, Ji Eun Jung
Abstract: Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
September 12, 2023
Assignee:
IntoCell, Inc.
Inventors:
Taekyo Park, Sung Ho Woo, Sunyoung Kim, Suho Park, Jongun Cho, Doohwan Jung, Donghoon Seo, Jaeho Lee, Sangkwang Lee, Sanghyeon Yun, Hyang Sook Lee, Okku Park, Beomseok Seo
Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
September 5, 2023
Assignee:
Lantheus Medical Imaging, Inc.
Inventors:
Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.
Abstract: The present invention provides a method for the commercial presentation of a solution of gadolinium-DOTA that provides certain advantages over the known methods.
Type:
Grant
Filed:
October 26, 2020
Date of Patent:
August 22, 2023
Assignee:
GE HEALTHCARE AS
Inventors:
Karina Martha Langseth-Manrique, Arne Wang Aabye, Harald Laugen, Eva Krog Tamnes, Borge Mathisen
Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
Type:
Grant
Filed:
October 19, 2022
Date of Patent:
August 22, 2023
Assignee:
Vector Vitale IP LLC
Inventors:
Peter Novak, Maxim V. Temnikov, Oleksandr Balakin
Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
Type:
Grant
Filed:
October 28, 2022
Date of Patent:
July 25, 2023
Assignee:
RAYZEBIO, INC.
Inventors:
Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio
Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.
Type:
Grant
Filed:
July 19, 2021
Date of Patent:
July 4, 2023
Assignees:
UNIVERSITY OF THE FREE STATE, UNIVERSITAT ZURICH
Inventors:
Andreas Roodt, Roger Ariel Alberto, Angelo Frei, Petrus Pennie Mokolokolo, Robin Kim Bollinger, Alice Brink, Dumisani Vincent Kama
Abstract: A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents.
Type:
Grant
Filed:
November 12, 2019
Date of Patent:
June 27, 2023
Assignee:
BRACCO IMAGING S.P.A.
Inventors:
Zsolt Baranyai, Simona Ghiani, Alessandro Maiocchi, Ivan Hawala
Abstract: Methods of treating diseases caused by repeat DNA instability are described herein. The methods described herein can inhibit the further expansion of repeat DNA and, in some instances, reduce the size of the repeat DNA (e.g., reduce the number of repeats).
Type:
Grant
Filed:
August 12, 2017
Date of Patent:
June 13, 2023
Assignees:
Osaka University
Inventors:
Christopher E. Pearson, Masayuki Nakamori, Kazuhiko Nakatani
Abstract: The present invention provides an eco-friendly smart photosensitizer comprising a conjugate of hydroxypropyl methylcellulose and porfimer sodium photosensitizer, and a photo-stem cell therapy product comprising the photosensitizer. The photosensitizer of the present invention can be advantageously used in various fields including anticancer therapy, stem cell therapy, and the like, without side effects.
Type:
Grant
Filed:
November 26, 2020
Date of Patent:
May 23, 2023
Inventors:
Jin Wang Kim, Jung Ok Lee, Hyun Ji Kim, Hyun Woo Kim
Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
Type:
Grant
Filed:
February 1, 2022
Date of Patent:
April 18, 2023
Assignee:
MYELOID THERAPEUTICS, INC.
Inventors:
Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (?-synuclein, A-synuclein, aSynuclein, A-syn, ?-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
April 11, 2023
Assignee:
AC IMMUNE SA
Inventors:
Jérôme Molette, Emanuele Gabellieri, Vincent Darmency
Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.
Type:
Grant
Filed:
September 25, 2020
Date of Patent:
April 11, 2023
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
February 14, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
Abstract: Compositions comprising high levels of high specific activity copper-64, and process for preparing said compositions. The compositions comprise from about 2 Ci to about 15 Ci of copper-64 and have specific activities up to about 3800 mCi copper-64 per microgram of copper. The processes for preparing said compositions comprise bombarding a nickel-64 target with a low energy, high current proton beam, and purifying the copper-64 from other metals by a process comprising ion exchange chromatography or a process comprising a combination of extraction chromatography and ion exchange chromatography.
Type:
Grant
Filed:
August 24, 2022
Date of Patent:
February 14, 2023
Assignee:
Curium US LLC
Inventors:
David Pipes, Lauren Radford, William Uhland, Brian Regna, Craig Brunkhorst
Abstract: Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.
Type:
Grant
Filed:
August 4, 2020
Date of Patent:
February 7, 2023
Assignee:
Bilix Co., Ltd.
Inventors:
Sang Yong Jon, Dong Yun Lee, Yong Hyun Lee, Jin Yong Kim